Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hunan Er-Kang Pharmaceutical Co (300267) Fair Value & Analysis

Healthcare · CN · Market cap 7.3B CNY

Price¥3.47
Fair Value¥1.02
Upside-70.6%
Quality93/100
Evidence: Medium Range ¥0.8100 – ¥1.42

Fair value as of: Jun 24, 2026

Analysis

Hunan Er-Kang Pharmaceutical Co (300267) currently trades at ¥3.47, while our model-based Fair Value estimate is ¥1.02 — implying the stock looks roughly 70.6% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Hunan Er-Kang Pharmaceutical Co (300267) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.02 versus a price of ¥3.47 — about −71% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300267?
Our 21-model fair value for Hunan Er-Kang Pharmaceutical Co is ¥1.02 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥3.47.
What is the quality score of 300267?
Hunan Er-Kang Pharmaceutical Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.